Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hypotonic saline, specifically a 0.65% sodium chloride solution, is an intravenous hydration fluid used in clinical settings. In the context of the PANTER trial (NCT02311231) led by St. Antonius Hospital, it was evaluated as a prophylactic hydration strategy to prevent contrast-induced nephropathy (CIN) in high-risk patients, such as those with chronic kidney disease undergoing transcatheter aortic valve implantation (TAVI). The treatment aims to reduce the risk of acute kidney injury by expanding intravascular volume, which maintains renal blood flow and promotes the diuresis of iodinated contrast media, thereby minimizing direct toxic effects on renal tubules.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hypotonic saline (f2749b).